Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California. Show more

1599 Industrial Road, San Carlos, CA, 94070, United States

https://biomeafusion.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

99.05M

52 Wk Range

$0.87 - $2.99

Previous Close

$1.36

Open

$1.37

Volume

575,261

Day Range

$1.32 - $1.38

Enterprise Value

64.63M

Cash

34.82M

Avg Qtr Burn

-10.03M

Insider Ownership

7.15%

Institutional Own.

40.02%

Qtr Updated

06/30/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Icovamenib + GLP-1 based therapy Details Type 2 diabetes	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BMF-219 (icovamenib) + GLP-1-based therapy Details Severe insulin-deficient type 2 diabetes patients	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BMF-219 (icovamenib) Details Type 1 diabetes	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Icovamenib + Semaglutide (BMF-219) (Menin GLP-1 Combination) Details Obesity	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Icovamenib (BMF-219) (Menin Inhibitor) Details Type 1 Diabetes (Diagnosed Within Past 3 Years)	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BMF-219 (icovamenib) Details Type 2 diabetes	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BMF-650 (GLP-1 RA) Details Obese, otherwise healthy volunteers	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BMF-500 Details Leukemia	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BMF-219 (icovamenib) Details Acute myeloid leukemia, Acute lymphoblastic leukemia	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BMF-219 (icovamenib) Details Solid tumor/s, Colorectal cancer , Pancreatic cancer, Non-small cell lung carcinoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.